Dr. Christopher M. Pieczonka, MD

Dr. Pieczonka practices at Associated Medical Professionals of NY in Syracuse, New York.

Dr. Pieczonka's NPI, 1376530121, was assigned on October 5, 2005. Dr. Pieczonka graduated from State University of New York at Buffalo School of Medicine in 1997. Dr. Pieczonka holds New York license 227123.

Dr. Pieczonka's primary practice is Associated Medical Professionals of NY, at 1226 E Water St, Syracuse, NY 13210 in Onondaga County. The practice phone is (315) 478-2887.

Dr. Pieczonka's primary practice is Associated Medical Professionals of NY in Syracuse, New York. Dr. Pieczonka is also affiliated with St. Joseph's Health Hospital. The medical group on file is Associated Medical Professionals of NY. Dmand AI also links Dr. Pieczonka to 4 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Pieczonka practices, 7 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Pieczonka's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Pieczonka is licensed in New York.

CMS data shows 29,830 Medicare services from Dr. Pieczonka across 29 procedure codes in 2024, for 1,125 Medicare patients. Medicare paid $935,056 for them. Every service was in an office.

CMS counts 1,125 Medicare patients who saw Dr. Pieczonka in 2024. The largest group is 65 to 74, with 500 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.46, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Pieczonka's median patient age at 73, with 11% women.

In 2024, Dr. Pieczonka wrote 2,459 Medicare Part D claims for 392 patients. 56% of them were for generic drugs. CMS names the drug for 2,327 of them, across 24 drugs with 11 or more claims each, at $10,650,721 in total drug cost. In 2023, CMS named 2,758 claims across 26 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Pieczonka for performance year 2024, reported as part of a group. Dr. Pieczonka accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Pieczonka as offering telehealth.

Dmand AI links 28 papers to Dr. Pieczonka, published from 2014 to 2025. 2020 was the busiest year, with 6. The most frequent topics are Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant and Genetic Testing. Dr. Pieczonka has published most often in Rev Urol. Dr. Pieczonka's most frequent co-authors are Raoul S. Concepcion, MD, Lawrence I. Karsh, MD and Ronald F. Tutrone, MD.

Dmand AI links Dr. Pieczonka to 12 clinical trials, 2 of them phase 1/2 studies. 3 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Neoplasm Metastasis. Eli Lilly and Company sponsors the most, 3. Open Payments lists research payments to Dr. Pieczonka that name 4 trials.

CMS Open Payments shows 1,711 general payments to Dr. Pieczonka from 68 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 50% of the total. Janssen Pharmaceuticals, Inc paid the most, $272,721. It also lists 65 research payments totaling $72,668 from 2016 to 2025, naming 4 clinical trials.

Dr. Pieczonka graduated from State University of New York at Buffalo School of Medicine in 1997.